Published in J Biomol Struct Dyn on June 26, 2012
Structure and flexibility of nanoscale protein cages designed by symmetric self-assembly. J Am Chem Soc (2013) 0.90
Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo. J Immunol (2013) 0.87
Design, Synthesis and Inhibitory Activity of Photoswitchable RET Kinase Inhibitors. Sci Rep (2015) 0.83
Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3. Biopolymers (2014) 0.82
Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain. Eur J Med Chem (2013) 0.82
Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology. PLoS One (2013) 0.81
Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer. Chem Biol Drug Des (2014) 0.78
Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors. Future Oncol (2015) 0.76
Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells. Eur J Med Chem (2016) 0.76
Characterizing the Hot Spots Involved in RON-MSPβ Complex Formation Using In Silico Alanine Scanning Mutagenesis and Molecular Dynamics Simulation. Adv Pharm Bull (2017) 0.75
Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells. Protein Expr Purif (2015) 0.75
A Caged Ret Kinase Inhibitor and its Effect on Motoneuron Development in Zebrafish Embryos. Sci Rep (2015) 0.75
MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2009) 53.36
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics (2005) 34.83
ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 16.73
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature (2007) 9.12
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature (2003) 6.78
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell (2004) 6.12
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell (2002) 5.64
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
Tyrosine kinase inhibition: an approach to drug development. Science (1995) 4.82
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res (2008) 3.93
A dissection of specific and non-specific protein-protein interfaces. J Mol Biol (2004) 3.77
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res (2001) 3.62
Structure of the extracellular region of HER3 reveals an interdomain tether. Science (2002) 3.19
Hot spots--a review of the protein-protein interface determinant amino-acid residues. Proteins (2007) 3.18
Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell (2007) 2.83
Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. Mol Cell Biol (2005) 2.35
HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol (2010) 2.24
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst (2007) 2.11
Kinetic, equilibrium, and thermodynamic analysis of macromolecular interactions with BIACORE. Methods Enzymol (2000) 2.01
Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys (2008) 1.97
Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem (2009) 1.91
All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J Cell Sci (2008) 1.74
Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. Mol Cell Biol (2010) 1.63
The molecular architecture of protein-protein binding sites. Curr Opin Struct Biol (2007) 1.59
Protein-protein interactions in human disease. Curr Opin Struct Biol (2005) 1.52
Predicting druggable binding sites at the protein-protein interface. Drug Discov Today (2008) 1.45
HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res (2003) 1.42
Modeling the effects of HER/ErbB1-3 coexpression on receptor dimerization and biological response. Biophys J (2006) 1.36
Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov Today (2009) 1.27
Structure-based and ligand-based drug design for HER 2 receptor. J Biomol Struct Dyn (2010) 1.21
Disabling receptor ensembles with rationally designed interface peptidomimetics. J Biol Chem (2002) 1.21
Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J Biol Chem (2004) 1.10
Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. J Med Chem (2001) 1.09
Drugs targeting protein-protein interactions. ChemMedChem (2006) 1.03
Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol (2007) 1.02
HER2 therapy. HER2 (ERBB2): functional diversity from structurally conserved building blocks. Breast Cancer Res (2007) 1.02
Weighted equation and rules--a novel concept for evaluating protein-ligand interaction. J Biomol Struct Dyn (2009) 0.98
Mutagenesis reveals a role for epidermal growth factor receptor extracellular subdomain IV in ligand binding. J Biol Chem (1999) 0.96
Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines. Chem Biol Drug Des (2009) 0.92
Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat (2011) 0.92
Structure of the complex between HER2 and an antibody paratope formed by side chains from tryptophan and serine. J Mol Biol (2010) 0.91
Role of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivation. Proc Natl Acad Sci U S A (2003) 0.89
Protein-protein interactions: principles, techniques, and their potential role in new drug development. J Biomol Struct Dyn (2011) 0.88
HER2 inhibition: from discovery to clinical practice. Clin Cancer Res (2007) 0.86
A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein. J Biomol Struct Dyn (2010) 0.85
Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines. Medchemcomm (2011) 0.84
Application of surface plasmon resonance spectroscopy to study G-protein coupled receptor signalling. Methods Mol Biol (2010) 0.83
Grafting of protein-protein interaction epitope. J Biomol Struct Dyn (2000) 0.80
Understanding structural/functional properties of immunoconjugates for cancer therapy by computational approaches. J Biomol Struct Dyn (2008) 0.80
Targeting the dimerization of epidermal growth factor receptors with small-molecule inhibitors. Chem Biol Drug Des (2010) 0.79
Molecular mechanisms of protein-protein recognition: whether the surface placed charged residues determine the recognition process? J Biomol Struct Dyn (2001) 0.79
Bacterial cytoplasm production of an EGFP-labeled single-chain Fv antibody specific for the HER2 human receptor. J Biomol Struct Dyn (2011) 0.77
Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine (2005) 1.42
Antibody to ricin a chain hinders intracellular routing of toxin and protects cells even after toxin has been internalized. PLoS One (2013) 1.06
Protective effects of anti-ricin A-chain antibodies delivered intracellularly against ricin-induced cytotoxicity. World J Biol Chem (2010) 0.99
Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates. PLoS One (2012) 0.89
Horizontal transmission of Candida albicans and evidence of a vaccine response in mice colonized with the fungus. PLoS One (2011) 0.88
Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain. Eur J Med Chem (2013) 0.82
Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3. Biopolymers (2014) 0.82
Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity. Pharm Res (2006) 0.82
Immunosuppression by co-stimulatory molecules: inhibition of CD2-CD48/CD58 interaction by peptides from CD2 to suppress progression of collagen-induced arthritis in mice. Chem Biol Drug Des (2013) 0.78
Experimental support for an immunological approach to the search for life on other planets. Astrobiology (2005) 0.78
Controllable in situ synthesis of magnetite coated silica-core water-dispersible hybrid nanomaterials. Langmuir (2013) 0.76
Peptides and peptidomimetics as immunomodulators. Immunotherapy (2014) 0.75